SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive...
Back to back announcements of good news. This is a relatively new one for me in this space, but the news (in links below) of the NIH grant followed by the FDA approval of an additional indication will make following today's stock-price-action of interest! www.scynexis.com www.scynexis.com (NOTE: NOT ADVICE IN ANYWAY!! JUST FOOD FOR THOUGHT AND DISCUSSION!!)
SCYX: Scynexis 2022-02-10 07:36:33 SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
Scynexis to Initiate a Phase 3 Study of Oral Ibrexafungerp as a Step-Down Treatment for Invasive Candidiasis Following Meeting With FDA SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the...
SCYX chart. Burry bought in, accounting for the 25% gain. Looking for a gain in share price after breakout of multiple-month decreasing wedge.
SCYX: Scynexis 2021-03-02 07:30:00 SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
SCYX has been consolidating into this bullish wedge for months now. With upcoming catalysts, such as the first FDA approval for their ibrexafungerp antifungal in Q1 2021 and other catalyst announcements potentially in Q4 2020, this looks prime for a large break out over $10. I will be buying at any price within this wedge with a target >$20 for profit taking.
Loading up in the $4's possibly $3's and will hold until New Year. Its a buy here!
NASDAQ:SCYX Big picture: it is currently in uptrend channel. Higher highs and lower lows, tightening pattern. Smaller picture, its underneath EMAs, so that's a bit concerning. But volume looks to be increasing more steadily. A bit of fundamental analysis, the results from one late stage study should be out this month with positive results so that will be a...
Risky biotech play, double bottom hit today @ 1.05
6 month cup and handle here with a weekly breakout with massive volume validating the move, if price manage to close above the newly formed support, here's a great long opportunity, the SL is based on an intraday open price. the cup and handle suggest a higher target but there’s an important resistance to beat first so that would the TP1.